134 related articles for article (PubMed ID: 21182503)
21. An evaluation of clinical and histopathological status in paucibacillary leprosy patients after completion of fixed duration therapy.
Mathew D; Kishore BN; Shwethadri GK; Sukumar ; Shetty NJ
Indian J Lepr; 2004; 76(1):11-8. PubMed ID: 15527055
[TBL] [Abstract][Full Text] [Related]
22. Fixed duration MDT in paucibacillary leprosy.
Mathai R; George S; Jacob M
Int J Lepr Other Mycobact Dis; 1991 Jun; 59(2):237-41. PubMed ID: 2071980
[TBL] [Abstract][Full Text] [Related]
23. Long-term follow up of multibacillary leprosy patients with high BI treated with WHO/MDT regimen for a fixed duration of two years.
Shaw IN; Natrajan MM; Rao GS; Jesudasan K; Christian M; Kavitha M
Int J Lepr Other Mycobact Dis; 2000 Dec; 68(4):405-9. PubMed ID: 11332283
[TBL] [Abstract][Full Text] [Related]
24. Multidrug therapy in leprosy can prevent relapse--a retrospective study.
Biswas S; Mondal KK
Indian J Lepr; 2002; 74(4):313-8. PubMed ID: 12624979
[TBL] [Abstract][Full Text] [Related]
25. Studies on risk of leprosy relapses in China: relapses after treatment with multidrug therapy.
Chen XS; Li WZ; Jiang C; Ye GY
Int J Lepr Other Mycobact Dis; 1999 Dec; 67(4):379-87. PubMed ID: 10700911
[TBL] [Abstract][Full Text] [Related]
26. An investigation of attitudes, beliefs and behaviour of leprosy patients, family members and PHC workers towards multidrug therapy in Yangzhou and Dongtai Districts of China.
Chen XS; Ye GY; Jiang C; Li WZ; Bian J; Wang H; Chen W
Lepr Rev; 1997 Jun; 68(2):155-61. PubMed ID: 9217355
[TBL] [Abstract][Full Text] [Related]
27. Epidemiological shift in leprosy in a rural district of central India following introduction of multi-drug therapy (April 1986 to March 1992 and April 1992 to March 2002).
Pandey A; Uddin MJ; Patel R
Lepr Rev; 2005 Jun; 76(2):112-8. PubMed ID: 16038244
[TBL] [Abstract][Full Text] [Related]
28. Study of HLA-DR expression on skin lesions of leprosy before and during multiple drug therapy.
Abdel Latif AM; Essa EA
Int J Lepr Other Mycobact Dis; 2002 Jun; 70(2):104-10. PubMed ID: 12211894
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of Prospective HLA-B*13:01 Screening to Prevent Dapsone Hypersensitivity Syndrome in Patients With Leprosy.
Liu H; Wang Z; Bao F; Wang C; Sun L; Zhang H; Yu G; Mi Z; Li J; Li L; Zhao Q; Yue Z; Zhao W; Yu W; Cao J; Xiong F; Wang Y; Chai Z; Cheng X; Zhang Y; Fu F; Lang X; Wang X; Irwanto A; Krismawati H; Fu X; Sun Y; You J; Liu J; Pan Q; Chu T; Liu D; Chen S; Shen J; Yan L; Zhang G; Liu J; Zhang F; ; Xiong L; Yang J; Li J; Ke W; Li M; Ning Y; Xiong J; Li M; Xiong M; Yang B; Duan Q; Wang H; Li W; Kuang Y; Li J; Wang L; Cao Q; Xiao P; Xiao B; Zhang L; Lin Z; Wang Y; Shen Y; Yan L; Wu W; Zheng H; Zhan X; Li W; Shang X; Xu Y; Liu Q
JAMA Dermatol; 2019 Jun; 155(6):666-672. PubMed ID: 30916737
[TBL] [Abstract][Full Text] [Related]
30. The contribution of "cure by dapsone monotherapy' to the reduction of prevalence of leprosy in the State of Orissa, India, 1983-1993.
Patnaik PK; McDougall AC
Indian J Lepr; 1996; 68(3):223-6. PubMed ID: 8889607
[TBL] [Abstract][Full Text] [Related]
31. Field trial on efficacy of supervised monthly dose of 600 mg rifampin, 400 mg ofloxacin and 100 mg minocycline for the treatment of leprosy; first results.
Mane I; Cartel JL; Grosset JH
Int J Lepr Other Mycobact Dis; 1997 Jun; 65(2):224-9. PubMed ID: 9251595
[TBL] [Abstract][Full Text] [Related]
32. New lesions after MDT in PB and MB leprosy: a report of 28 cases.
Kar HK; Sharma P
Indian J Lepr; 2008; 80(3):247-55. PubMed ID: 19432355
[TBL] [Abstract][Full Text] [Related]
33. Relapses among leprosy patients treated with multidrug therapy: experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia; practical difficulties with diagnosing relapses; operational procedures and criteria for diagnosing relapses.
Becx-Bleumink M
Int J Lepr Other Mycobact Dis; 1992 Sep; 60(3):421-35. PubMed ID: 1474281
[TBL] [Abstract][Full Text] [Related]
34. Trends in leprosy over fifty years in Gudiyatham Taluk, Vellore, Tamil Nadu.
Norman G; Raja Samuel Bhushanam JD; Samuel P
Indian J Lepr; 2006; 78(2):167-85. PubMed ID: 16927851
[TBL] [Abstract][Full Text] [Related]
35. Short-course multi-drug therapy for leprosy patients.
Puavilai S; Timpatanapong P
J Med Assoc Thai; 1989 Jan; 72(1):33-6. PubMed ID: 2656897
[TBL] [Abstract][Full Text] [Related]
36. Relapse as histoid leprosy after receiving multidrug therapy (MDT); a report of three cases.
Shaw IN; Ebenezer G; Rao GS; Natrajan MM; Balasundaram B
Int J Lepr Other Mycobact Dis; 2000 Sep; 68(3):272-6. PubMed ID: 11221089
[TBL] [Abstract][Full Text] [Related]
37. Long-term efficacy of 2 year WHO multiple drug therapy (MDT) in multibacillary (MB) leprosy patients.
Cellona RV; Balagon MF; dela Cruz EC; Burgos JA; Abalos RM; Walsh GP; Topolski R; Gelber RH; Walsh DS
Int J Lepr Other Mycobact Dis; 2003 Dec; 71(4):308-19. PubMed ID: 14763888
[TBL] [Abstract][Full Text] [Related]
38. Selection of MDT strategies through epidemiometric modeling.
Lechat MF; Declercq EE; Misson CB; Vellut CM
Int J Lepr Other Mycobact Dis; 1990 Jun; 58(2):296-301. PubMed ID: 2115904
[TBL] [Abstract][Full Text] [Related]
39. Study of multidrug therapy in paucibacillary leprosy.
Kar PK; Sohi AS
J Indian Med Assoc; 1989 Feb; 87(2):34-6. PubMed ID: 2674283
[TBL] [Abstract][Full Text] [Related]
40. Prospective study on the relationship between intensive bactericidal therapy and leprosy reactions.
Groenen G; Janssens L; Kayembe T; Nollet E; Coussens L; Pattyn SR
Int J Lepr Other Mycobact Dis; 1986 Jun; 54(2):236-44. PubMed ID: 3722962
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
